195 related articles for article (PubMed ID: 26010511)
1. Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies.
Yang Z; Li J; Liu Q; Yuan T; Zhang Y; Chen LQ; Lou Q; Sun Z; Ying H; Xu J; Dimitrov DS; Zhang MY
PLoS One; 2015; 10(5):e0126428. PubMed ID: 26010511
[TBL] [Abstract][Full Text] [Related]
2. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
3. Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development.
Yuan T; Li J; Zhang Y; Wang Y; Streaker E; Dimitrov DS; Zhang MY
Vaccine; 2011 Sep; 29(40):6903-10. PubMed ID: 21807049
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
5. A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins.
Yuan T; Li J; Zhang MY
MAbs; 2011; 3(4):402-7. PubMed ID: 21540646
[TBL] [Abstract][Full Text] [Related]
6. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.
Hoot S; McGuire AT; Cohen KW; Strong RK; Hangartner L; Klein F; Diskin R; Scheid JF; Sather DN; Burton DR; Stamatatos L
PLoS Pathog; 2013 Jan; 9(1):e1003106. PubMed ID: 23300456
[TBL] [Abstract][Full Text] [Related]
7. Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies.
Carbonetti S; Oliver BG; Glenn J; Stamatatos L; Sather DN
PLoS One; 2014; 9(1):e86905. PubMed ID: 24466285
[TBL] [Abstract][Full Text] [Related]
8. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
[TBL] [Abstract][Full Text] [Related]
9. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
[TBL] [Abstract][Full Text] [Related]
10. Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates.
Chakrabarti BK; Feng Y; Sharma SK; McKee K; Karlsson Hedestam GB; Labranche CC; Montefiori DC; Mascola JR; Wyatt RT
J Virol; 2013 Dec; 87(24):13239-51. PubMed ID: 24067980
[TBL] [Abstract][Full Text] [Related]
11. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
Shrivastava T; Samal S; Tyagi AK; Goswami S; Kumar N; Ozorowski G; Ward AB; Chakrabarti BK
Vaccine; 2018 Mar; 36(12):1627-1636. PubMed ID: 29429810
[TBL] [Abstract][Full Text] [Related]
12. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
[TBL] [Abstract][Full Text] [Related]
13. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting.
Cheng C; Xu K; Kong R; Chuang GY; Corrigan AR; Geng H; Hill KR; Jafari AJ; O'Dell S; Ou L; Rawi R; Rowshan AP; Sarfo EK; Sastry M; Saunders KO; Schmidt SD; Wang S; Wu W; Zhang B; Doria-Rose NA; Haynes BF; Scorpio DG; Shapiro L; Mascola JR; Kwong PD
PLoS One; 2019; 14(4):e0215163. PubMed ID: 30995238
[TBL] [Abstract][Full Text] [Related]
14. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
[TBL] [Abstract][Full Text] [Related]
15. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
[TBL] [Abstract][Full Text] [Related]
16. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
17. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
18. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.
Xiao X; Chen W; Feng Y; Zhu Z; Prabakaran P; Wang Y; Zhang MY; Longo NS; Dimitrov DS
Biochem Biophys Res Commun; 2009 Dec; 390(3):404-9. PubMed ID: 19748484
[TBL] [Abstract][Full Text] [Related]
19. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]